Hence, we provide proof-of-concept evidences to support that pan-HER inhibitor such as afatinib might effectively inhibit EGFR/HER/Akt/MAPK pathways, which are activated in resistant CRC, as indicated by Khelwatty et al. [8]. Here, EGFR is linked to colorectal carcinoma.